Collegium Pharmaceutical (NASDAQ:COLL) Hits New 12-Month Low – What’s Next?

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) shares reached a new 52-week low on Thursday . The stock traded as low as $25.47 and last traded at $25.70, with a volume of 1122273 shares changing hands. The stock had previously closed at $25.98.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on COLL. Zacks Research cut shares of Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 28th. Wall Street Zen lowered Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. Truist Financial raised Collegium Pharmaceutical to a “strong-buy” rating in a research note on Monday, June 15th. Needham & Company LLC cut their price target on Collegium Pharmaceutical from $56.00 to $46.00 and set a “buy” rating on the stock in a report on Thursday, August 6th. Finally, Piper Sandler reissued a “neutral” rating and issued a $43.00 price objective (down from $45.00) on shares of Collegium Pharmaceutical in a research note on Friday, August 7th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat, Collegium Pharmaceutical presently has a consensus rating of “Moderate Buy” and an average target price of $52.60.

Collegium Pharmaceutical Price Performance

The company has a debt-to-equity ratio of 3.32, a current ratio of 1.03 and a quick ratio of 0.84. The business’s fifty day moving average price is $34.49 and its 200-day moving average price is $36.57. The stock has a market capitalization of $836.79 million, a price-to-earnings ratio of 20.73 and a beta of 0.73.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its earnings results on Thursday, August 6th. The specialty pharmaceutical company reported $1.92 earnings per share for the quarter, topping analysts’ consensus estimates of $1.72 by $0.20. Collegium Pharmaceutical had a net margin of 5.93% and a return on equity of 91.43%. The company had revenue of $199.88 million for the quarter, compared to analyst estimates of $199.62 million. During the same quarter in the prior year, the business posted $1.68 EPS. The firm’s revenue was up 6.3% compared to the same quarter last year. On average, research analysts forecast that Collegium Pharmaceutical, Inc. will post 6.76 EPS for the current year.

Institutional Trading of Collegium Pharmaceutical

Several institutional investors and hedge funds have recently modified their holdings of COLL. Group One Trading LLC bought a new position in shares of Collegium Pharmaceutical in the fourth quarter valued at approximately $28,000. Caitong International Asset Management Co. Ltd boosted its position in shares of Collegium Pharmaceutical by 205.3% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 635 shares of the specialty pharmaceutical company’s stock valued at $29,000 after buying an additional 427 shares during the last quarter. PNC Financial Services Group Inc. boosted its position in shares of Collegium Pharmaceutical by 42.2% during the first quarter. PNC Financial Services Group Inc. now owns 1,408 shares of the specialty pharmaceutical company’s stock valued at $47,000 after buying an additional 418 shares during the last quarter. Kemnay Advisory Services Inc. bought a new stake in Collegium Pharmaceutical during the fourth quarter worth $61,000. Finally, Mirae Asset Global Investments Co. Ltd. grew its holdings in Collegium Pharmaceutical by 26.1% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,536 shares of the specialty pharmaceutical company’s stock worth $71,000 after buying an additional 318 shares in the last quarter.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.